TY - JOUR
T1 - NHLRC2 variants identified in patients with fibrosis, neurodegeneration, and cerebral angiomatosis (FINCA)
T2 - characterisation of a novel cerebropulmonary disease
AU - Uusimaa, Johanna
AU - Kaarteenaho, Riitta
AU - Paakkola, Teija
AU - Tuominen, Hannu
AU - Karjalainen, Minna K.
AU - Nadaf, Javad
AU - Varilo, Teppo
AU - Uusi-Mäkelä, Meri
AU - Suo-Palosaari, Maria
AU - Pietilä, Ilkka
AU - Hiltunen, Anniina E.
AU - Ruddock, Lloyd
AU - Alanen, Heli
AU - Biterova, Ekaterina
AU - Miinalainen, Ilkka
AU - Salminen, Annamari
AU - Soininen, Raija
AU - Manninen, Aki
AU - Sormunen, Raija
AU - Kaakinen, Mika
AU - Vuolteenaho, Reetta
AU - Herva, Riitta
AU - Vieira, Päivi
AU - Dunder, Teija
AU - Kokkonen, Hannaleena
AU - Moilanen, Jukka S.
AU - Rantala, Heikki
AU - Nogee, Lawrence M.
AU - Majewski, Jacek
AU - Rämet, Mika
AU - Hallman, Mikko
AU - Hinttala, Reetta
N1 - Funding Information:
The authors would like to thank Professors Eric Shoubridge, Kalervo Hiltunen and Christer Betsholtz, Assistant Professor Michael Vanlandewijck, Adjunct Professor Siri Lehtonen and Dr. Riikka Pietilä for their expert advice and support and also Ms. Pirjo Keränen, Ms. Riitta Vuento, Ms. Maarit Haarala, Ms. Hanna Seppälä, Ms. Kirsi Säkkinen, the Transgenic Core Facility at Biocenter Oulu, and the Laboratory Animal Centre at the University of Oulu for their expert assistance. Biocenter Oulu Electron Microscopy core facility, a member of Biocenter Finland, is acknowledged for their help with EM analysis. The zebrafish work was carried out at University of Tampere core facility, supported by Biocenter Finland. The digital pathology scanner of Northern Finland Biobank Borealis was used in imaging the neuropathological findings. This work was conducted with support from the Research Council for Health of the Academy of Finland (JU, decision number 138566; RH, decision numbers 266498, 273790 and 303996; MH, decision number 1126662; LR, decision numbers 266457 and 272573); the Sigrid Juselius Foundation (JU, RH and MH); the Foundation for Paediatric Research, Finland (JU and MKK); the Alma and KA Snellman Foundation (JU and MKK); a Marie Curie International Outgoing Fellowship of the European Union’s Seventh Framework Programme (Grant agreement number 273669 [BioMit]) (RH); Foundation of the Finnish Anti-Tuberculosis Association (RK); the Jane and Aatos Erkko Foundation (MR); the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (MR); Special State Grants for Health Research in the Department of Paediatrics and Adolescence at Oulu University Hospital, Finland (JU); the National Heart, Lung and Blood Institute of the US National Institutes of Health under award number HL-54703 (LMN) and the Eudowood Foundation (LMN).
Funding Information:
Acknowledgements The authors would like to thank Professors Eric Shoubridge, Kalervo Hiltunen and Christer Betsholtz, Assistant Professor Michael Vanlandewijck, Adjunct Professor Siri Lehtonen and Dr. Riikka Pietilä for their expert advice and support and also Ms. Pirjo Keränen, Ms. Riitta Vuento, Ms. Maarit Haarala, Ms. Hanna Seppälä, Ms. Kirsi Säkkinen, the Transgenic Core Facility at Biocenter Oulu, and the Laboratory Animal Centre at the University of Oulu for their expert assistance. Biocenter Oulu Electron Microscopy core facility, a member of Biocenter Finland, is acknowledged for their help with EM analysis. The zebrafish work was carried out at University of Tampere core facility, supported by Biocenter Finland. The digital pathology scanner of Northern Finland Biobank Borealis was used in imaging the neuropathological findings. This work was conducted with support from the Research Council for Health of the Academy of Finland (JU, decision number 138566; RH, decision numbers 266498, 273790 and 303996; MH, decision number 1126662; LR, decision numbers 266457 and 272573); the Sigrid Juselius Foundation (JU, RH and MH); the Foundation for Paediatric Research, Finland (JU and MKK); the Alma and KA Snellman Foundation (JU and MKK); a Marie Curie International Outgoing Fellowship of the European Union’s Seventh Framework Programme (Grant agreement number 273669 [BioMit]) (RH); Foundation of the Finnish Anti-Tuberculosis Association (RK); the Jane and Aatos Erkko Foundation (MR); the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (MR); Special State Grants for Health Research in the Department of Paediatrics and Adolescence at Oulu University Hospital, Finland (JU); the National Heart, Lung and Blood Institute of the US National Institutes of Health under award number HL-54703 (LMN) and the Eudowood Foundation (LMN).
Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - A novel multi-organ disease that is fatal in early childhood was identified in three patients from two non-consanguineous families. These children were born asymptomatic but at the age of 2 months they manifested progressive multi-organ symptoms resembling no previously known disease. The main clinical features included progressive cerebropulmonary symptoms, malabsorption, progressive growth failure, recurrent infections, chronic haemolytic anaemia and transient liver dysfunction. In the affected children, neuropathology revealed increased angiomatosis-like leptomeningeal, cortical and superficial white matter vascularisation and congestion, vacuolar degeneration and myelin loss in white matter, as well as neuronal degeneration. Interstitial fibrosis and previously undescribed granuloma-like lesions were observed in the lungs. Hepatomegaly, steatosis and collagen accumulation were detected in the liver. A whole-exome sequencing of the two unrelated families with the affected children revealed the transmission of two heterozygous variants in the NHL repeat-containing protein 2 (NHLRC2); an amino acid substitution p.Asp148Tyr and a frameshift 2-bp deletion p.Arg201GlyfsTer6. NHLRC2 is highly conserved and expressed in multiple organs and its function is unknown. It contains a thioredoxin-like domain; however, an insulin turbidity assay on human recombinant NHLRC2 showed no thioredoxin activity. In patient-derived fibroblasts, NHLRC2 levels were low, and only p.Asp148Tyr was expressed. Therefore, the allele with the frameshift deletion is likely non-functional. Development of the Nhlrc2 null mouse strain stalled before the morula stage. Morpholino knockdown of nhlrc2 in zebrafish embryos affected the integrity of cells in the midbrain region. This is the first description of a fatal, early-onset disease; we have named it FINCA disease based on the combination of pathological features that include fibrosis, neurodegeneration, and cerebral angiomatosis.
AB - A novel multi-organ disease that is fatal in early childhood was identified in three patients from two non-consanguineous families. These children were born asymptomatic but at the age of 2 months they manifested progressive multi-organ symptoms resembling no previously known disease. The main clinical features included progressive cerebropulmonary symptoms, malabsorption, progressive growth failure, recurrent infections, chronic haemolytic anaemia and transient liver dysfunction. In the affected children, neuropathology revealed increased angiomatosis-like leptomeningeal, cortical and superficial white matter vascularisation and congestion, vacuolar degeneration and myelin loss in white matter, as well as neuronal degeneration. Interstitial fibrosis and previously undescribed granuloma-like lesions were observed in the lungs. Hepatomegaly, steatosis and collagen accumulation were detected in the liver. A whole-exome sequencing of the two unrelated families with the affected children revealed the transmission of two heterozygous variants in the NHL repeat-containing protein 2 (NHLRC2); an amino acid substitution p.Asp148Tyr and a frameshift 2-bp deletion p.Arg201GlyfsTer6. NHLRC2 is highly conserved and expressed in multiple organs and its function is unknown. It contains a thioredoxin-like domain; however, an insulin turbidity assay on human recombinant NHLRC2 showed no thioredoxin activity. In patient-derived fibroblasts, NHLRC2 levels were low, and only p.Asp148Tyr was expressed. Therefore, the allele with the frameshift deletion is likely non-functional. Development of the Nhlrc2 null mouse strain stalled before the morula stage. Morpholino knockdown of nhlrc2 in zebrafish embryos affected the integrity of cells in the midbrain region. This is the first description of a fatal, early-onset disease; we have named it FINCA disease based on the combination of pathological features that include fibrosis, neurodegeneration, and cerebral angiomatosis.
KW - Brain angiogenesis
KW - Central nervous system
KW - Cerebropulmonary disease
KW - Interstitial fibrosis
KW - Multi-organ disease
KW - Neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=85041529795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041529795&partnerID=8YFLogxK
U2 - 10.1007/s00401-018-1817-z
DO - 10.1007/s00401-018-1817-z
M3 - Article
C2 - 29423877
AN - SCOPUS:85041529795
SN - 0001-6322
VL - 135
SP - 727
EP - 742
JO - Acta neuropathologica
JF - Acta neuropathologica
IS - 5
ER -